CVS · CVS Health Corporation

Total revenues reached $100.4 billion in Q1 FY2026, up 6.2% from $94.6 billion in the prior year. This growth was primarily driven by an increase in the Government business, partially offset by a decline resulting from the Company's exit of the individual exchange business in 2026. Investors should note this strategic shift shapes the topline trajectory, balancing expansion in stable government programs against reduced exposure to volatile individual markets.

Gross profit advanced to $45.0 billion, a 3.3% increase from $43.5 billion, expanding the gross margin to 44.8%. This reflects effective cost management relative to revenue growth, underscoring the resilience of CVS Health's integrated model across pharmacy services and health care benefits.

Operating income saw a robust 38.7% rise to $4.7 billion from $3.4 billion, lifting the operating margin to 4.7%. The surge highlights underlying profitability momentum, as the absence of prior-year headwinds allowed better flow-through of topline gains to the bottom line. This improvement positions the Company to invest in growth while maintaining financial discipline.

Net income jumped 65.4% to $2.9 billion from $1.8 billion, with diluted EPS advancing 63.1% to $2.30 from $1.41. These gains demonstrate strong earnings power, directly enhancing per-share value for investors and supporting capital allocation flexibility.

On the cash flow front, net cash provided by operating activities totaled $4.2 billion, below the prior year's $4.6 billion primarily due to the timing of payments and receipts. After $849 million in capital expenditures (up from $743 million), free cash flow stood at $3.4 billion. This timing-driven softness does not signal operational weakness; rather, it reflects working capital dynamics common in health services. The Company maintains sufficient liquidity to meet short-term needs, with debt ratings influencing borrowing costs, capital access, and new store leases.